News | November 20, 2008

Chemotherapy Added to Radiotherapy Improves Survival for Low Grade Glioma Patients

November 20, 2008 – Adult patients with low grade glioma, a type of malignant brain tumor, had a better chance for survival if they received chemotherapy in addition to their course of radiotherapy, according to new research from the Radiation Therapy Oncology Group (RTOG) presented at the Society for Neuro-Oncology 13th Annual Meeting in Lake Las Vegas, NV.

“In this RTOG study we found that patients who survived at least one year from the completion of their treatment had much better survival and progression-free survival rates if they received chemotherapy in combination with radiotherapy,” said lead author Edward G. Shaw, M.D., of the Wake Forest University School of Medicine, Winston-Salem, NC. “This is the first multi-center prospective clinical trial to suggest a benefit from adjuvant therapy in this patient population.”

The 251 patients enrolled on RTOG 9802 were entered from academic and community-based sites in the U.S. and Canada from 1998 until 2002. High-risk low-grade glioma patients were randomized to receive either six weeks of radiotherapy alone or six weeks of radiotherapy followed by six cycles of chemotherapy consisting of procarbazine, CCNU and vincristine. RTOG found that for patients who survived at least one year post treatment, the risk of death was reduced by 43 percent and progression-free survival was reduced by 64 percent. With a median follow-up of 5.9 years, the overall five-year survival rate was 72 percent for the patients who received the additional chemotherapy as compared to 63 percent for those who received radiotherapy alone. The five-year progression-free survival rates were 63 percent versus 46 percent.

“There are a number of controversial issues in the management of low-grade gliomas, including which patients benefit from adjuvant therapy, and RTOG is one of the few groups that is able to study this patient population in a prospective manner,” said Walter J. Curran, Jr., the RTOG group chair, and the Lawrence W. Davis Professor and chair of the Department of Radiation Oncology in the Emory School of Medicine and Chief Medical Officer of the Emory Winship Cancer Institute. “With two-thirds of the patients still alive at five years we look forward to the long-term follow-up results for this study as well as analysis of the 1p19q genetic codeletion data.”

RTOG is a National Cancer Institute-funded national clinical trials group and is administered by the American College of Radiology.

For more information: www.rtog.org

Related Content

Proton Therapy Lowers Risk of Side Effects Compared to Conventional Radiation
News | Proton Therapy | May 23, 2019
Cancer patients getting proton therapy instead of traditional photon radiation are at a significantly lower risk of...
Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carri Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Feature | Henry Ford Hospital | May 21, 2019 | Dave Fornell, Editor
Henry Ford Hospital thought leaders regularly speak at the radiation oncology and radiology conferences about new res
Varian Acquiring Cancer Treatment Services International
News | Radiation Therapy | May 21, 2019
Varian Medical Systems announced it has entered into a definitive agreement to acquire India’s Cancer Treatment...
Videos | Radiation Therapy | May 21, 2019
This is a walk through of the ViewRay MRIdian MRI-guided radiotherapy system installed at ...
Partial Breast Irradiation Effective, Convenient Treatment Option for Low-Risk Breast Cancer
News | Radiation Therapy | May 20, 2019
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast...
New Method Improves Ability to Measure and Maximize Radiation Therapy Dose
News | Radiation Therapy | May 14, 2019
Delivering just the right dose of radiation for cancer patients is a delicate balance in their treatment regime....
Sponsored Content | Videos | Radiation Oncology | May 13, 2019
At ASTRO 2018, Accuray showcased new patient-fi
Radiotherapy After Chemo May Improve Survival in Advanced Hodgkin's Lymphoma Patients
News | Radiation Therapy | May 10, 2019
Patients with advanced Hodgkin's lymphoma who have large tumors at the time of diagnosis may benefit from radiotherapy...
IBA Partnering to Develop Advanced Digital Proton Therapy Technologies in Belgium
News | Proton Therapy | May 10, 2019
IBA (Ion Beam Applications SA) announced a research agreement with Skandionkliniken, Université Catholique de Louvain...